

## STRAX - Rebound Awaits

Sales and profits in Q2 were lower than our estimates. While the gross margin is still under pressure due to several temporary reasons, the company continues to improve on cost-consciousness. We lower estimates for both costs and sales and maintain our valuation.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**STRAX - Rebound Awaits**